<DOC>
	<DOCNO>NCT03008642</DOCNO>
	<brief_summary>The optimized CO-Rebreathing efficient method evaluate red cell mass use vast majority study sport medicine . However , method never evaluate large scale diagnosis primitive secondary polycythemia . The standard procedure evaluate red cell mass base isotopic measurement use Cr51-labelled red cell , lack availability many center highlight need non-invasive rapid alternative method . The purpose study evaluate validate CO-Rebreathing method set indication .</brief_summary>
	<brief_title>CO-Rebreathing Comparison Isotopic Red Cell Volume Determination Diagnosis Primitive Secondary Polycythemia</brief_title>
	<detailed_description>The definition true polycythemia stricto sensu increase red cell mass ( RCM ) 125 % expect value depend size weight patient . However , measurement require isotopic label red cell available hospital . Therefore , diagnosis polycythemia , particularly Polycythemia Vera ( PV ) base routine red blood cell parameter , i.e . hemoglobin level hematocrit . If parameter efficient mark polycythemia , discrepancy observe milder case . Two situation RCM evaluation particularly require described : - In patient hematocrit level 52 60 % ( men ) 48 56 % ( woman ) order limit invasive investigation patient confirm polycythemia diagnosis - In JAK2V617F positive myeloproliferative neoplasm ( MPN ) hematocrit hemoglobin level PV cut-off order discriminate mask PV essential thrombocythemia CO-Rebreathing fast , non invasive alternative method RCM evaluation . It base high affinity carbon monoxide ( CO ) hemoglobin . The decrease HbCO percentage CO inhalation dependent total hemoglobin mass RCM obtain . The investigator propose tri-centric study evaluate CO-Rebreathing alternative tool measure RCM diagnosis polycythemia two category patient describe .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<criteria>1 . Adult patient 2 . Informed consent obtain 3 . Requirement isotopic red cell mass determination : Hematocrit 52 60 % ( men ) 48 56 % ( woman ) argument PV ( JAK2V617F negative , EPO level normal/high ) . b Patients JAK2V617F positive MPN hematocrit level 46 50 % ( woman ) 48 52 % men . 4 . No recent vascular event ( &lt; 6 mois ) 5 . No unstable coronaropathy 6 . Non smoke since 24 hour . 7 . ECOG &lt; 2 8 . Negativity pregnancy test/effective contraception childbearing age woman , 9 . Health insurance 1 . Recent venous event &lt; 1 month , cerebral stroke &lt; 6 mois ) 2 . Evolutive cardiopathy ( &lt; 6 month ) 3 . Chronic Respiratory failure 4 . Smokers withdrawal last 24 hour CORebreathing 5 . Basal HbCO &gt; 7 % day CORebreathing 6 . Pregnant breast feed woman 7 . Patient enable give inform consent 8 . Inclusion interventional clinical trial last three month . 9 . Any contraindication lung function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Polycythemia</keyword>
	<keyword>CO-Rebreathing</keyword>
	<keyword>red cell mass determination</keyword>
	<keyword>myeloproliferative neoplasm</keyword>
</DOC>